Biosimilars

On May 23, 2022, the Association for Accessible Medicines (AAM) and its Biosimilars Council urged the Federal Trade Commission (FTC) to investigate the competitive impact of pharmacy benefit managers (PBMs) and their various abusive behaviors that undermine patient access to safe, affordable pharmaceutical care. Read More ›

Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many pharmacy benefit managers and health plans have been slow to prioritize biosimilars, leaving savings on the table. Read More ›

This past year, the COVID-19 pandemic continued to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums. Read More ›

A real-world retrospective study (Canadian population) showed that patients with HER2-positive neoadjuvant early breast cancer treated with trastuzumab-dkst versus trastuzumab achieved similar pCR rates. Read More ›

The results of the cost-efficiency analysis within the Centers for Medicare & Medicaid Services Oncology Care Model indicate that switching from reference pegfilgrastim to pegfilgrastim-jmdb provided cost-savings that could potentially be reallocated to food and transportation support. Read More ›

Preliminary findings of this retrospective study indicate that treatment with bevacizumab reference product may be associated with a higher risk for hypertension and proteinuria, whereas treatment with bevacizumab biosimilars correlated with shorter onset of these adverse events. Read More ›

A retrospective study conducted in Poland confirmed that treatment with trastuzumab-anns was associated with an acceptable cardiac safety profile, even when switching from trastuzumab reference or when combined with pertuzumab. Read More ›

The findings from a small, retrospective study suggest that same-day pegfilgrastim-cbqv was a safe and effective alternative to standard administration 24 hours postchemotherapy for the primary and secondary prophylaxis of febrile neutropenia with myelosuppressive chemotherapy in patients with breast cancer. Read More ›

Real-world evidence indicates robust biosimilar uptake of the first FDA-approved bevacizumab biosimilar, bevacizumab-awwb, across its approved indications, including metastatic colorectal cancer and non–small-cell lung cancer. Read More ›

The findings of a retrospective observational study on healthcare resource utilization and cost patterns after formulary conversion to a biosimilar indicate that overall results may be driven by behavior at initial formulary switch. Read More ›

Page 1 of 8

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: